Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

First COVID-19 wave in the province of Bergamo, Italy: epidemiological and clinical characteristics, outcome and management of the first hospitalized patients

Donida et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09034-4
Jan 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 47% Improvement Relative Risk HCQ for COVID-19  Donida et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 723 patients in Italy (February - May 2020) Lower mortality with HCQ (not stat. sig., p=0.1) c19hcq.org Donida et al., BMC Infectious Diseases, Jan 2024 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now with p < 0.00000000001 from 411 studies, recognized in 46 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19hcq.org
Retrospective 723 hospitalized COVID-19 patients in Italy showing lower mortality with antirheumatic disease therapy, without statistical significance. Authors do not specify what medications are included, only mentioning HCQ/CQ which may represent most/all of the group.
risk of death, 47.0% lower, HR 0.53, p = 0.10, treatment 180 of 548 (32.8%), control 101 of 175 (57.7%), NNT 4.0, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Donida et al., 31 Jan 2024, retrospective, Italy, peer-reviewed, 4 authors, study period 21 February, 2020 - 31 May, 2020. Contact: bianca_donida@asst-bgovest.it.
This PaperHCQAll
First COVID-19 wave in the province of Bergamo, Italy: epidemiological and clinical characteristics, outcome and management of the first hospitalized patients
Bianca Maria Donida, Flavia Simonetta Pirola, Roberto Opizzi, Peter Assembergs
BMC Infectious Diseases, doi:10.1186/s12879-024-09034-4
Background Northern Italy was the first European country affected by the spread of the SARS-CoV-2, with the epicenter in the province of Bergamo. Aim This study aims to analyze the characteristics of patients who experienced more severe symptoms during the first wave of COVID-19 pandemic. Materials and methods We retrospectively collected epidemiological and clinical data on patients with laboratoryconfirmed wild-type SARS-CoV-2 infection who were admitted to the "ASST Bergamo Ovest" hospital between February 21 and May 31, 2020. Results A total of seven hundred twenty-three inpatients met the eligible criteria and were included in the study cohort. Among the inpatients who survived, the average hospital length of stay was more than two weeks, with some lasting up to three months. Among the 281 non-survivors, death occurred in 50% within five days. Survivors were those whose first aid operators recorded higher oxygen saturation levels at home. The request for first aid assistance came more than one week after symptom onset, within three days in 10% of cases. Conclusion In similar future scenarios, based on our data, if we aim to enhance the survival rate, we need to improve the territorial healthcare assistance and admit to hospitals only those patients who are at risk of severe illness requiring specialized and urgent interventions within two, three, or, at most, five days from the onset of symptoms. This implies that the crucial factor is, has been, and will be the ability of a healthcare system to react promptly in its entirety within a few days.
Abbreviations Supplementary Information The online version contains supplementary material available at https://doi. org/10.1186/s12879-024-09034-4. Supplementary Material 1 Author contributions PA defined the area of interest, and he delineated the research's project. BMD organized the work, investigated hospital discharge records, medical charts, and pathological reports, manually implementing the database. RO extracted Declarations Ethics approval and consent to participate This study was submitted to and approved by the Ethics Committee of Bergamo (Bergamo, BG, Italy) with the procedure's reference "096/22". All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s) in accordance with the approved ethical standards for retrospective observational study without drugs. Consent for publication Not Applicable. Competing interests The authors declare no competing interests. Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Cattelan, Meco, Clinical characteristics and laboratory biomarkers changes in COVID-19 patients requiring or not intensive or sub-intensive care: a comparative study, BMC Infectious Diseases
Collaborators, Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality 2020-21, The Lancet
Control, Case definition for coronavirus disease 2019
Elshazli, Toraih, Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: a meta-analysis of 6320 patients, PLoSONE
Ibanez-Samaniego, Bighelli, Elevation of liver fibrosis index FIB-4 is associated with poor clinical outcomes in patients with COVID-19, J infect Dis, doi:10.1093/infdis/jiaa355
Izcovich, Ragusa, Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review, PLoSONE
Kermali, Khalsa, The role of biomarkers in diagnosis of COVID-19-A systematic review, Life Sciences
Lee, Mayberry, Crapo, Jensen, The accuracy of pulse oximetry in the emergency department, Am J Emerg Med, doi:10.1053/ajem.2000.7330
Ma, Cheng, Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients, Crit Care
Marin, Aghagoli, Predictors of COVID-19 severity: a literature review, Rev Med Virol
Ministry, Health, Report Vaccini Anti COVID-19
Pdw, Fumeaux, Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort, EClinicalMedicine
Riccioni, Raccomandazioni Di Etica Clinica per l'ammissione a trattamenti intensivi e per la loro sospensione, in condizioni eccezionali di squilibrio tra necessità e risorse disponibili, recenti prog Med, doi:10.1701/3347.33183
{ 'indexed': {'date-parts': [[2024, 2, 1]], 'date-time': '2024-02-01T00:38:33Z', 'timestamp': 1706747913159}, 'reference-count': 26, 'publisher': 'Springer Science and Business Media LLC', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2024, 1, 31]], 'date-time': '2024-01-31T00:00:00Z', 'timestamp': 1706659200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2024, 1, 31]], 'date-time': '2024-01-31T00:00:00Z', 'timestamp': 1706659200000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Northern Italy was the first European country affected by the spread ' 'of the SARS-CoV-2, with the epicenter in the province of Bergamo.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Aim</jats:title>\n' ' <jats:p>This study aims to analyze the characteristics of patients who ' 'experienced more severe symptoms during the first wave of COVID-19 pandemic.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Materials and methods</jats:title>\n' ' <jats:p>We retrospectively collected epidemiological and clinical data on ' 'patients with laboratory-confirmed wild-type SARS-CoV-2 infection who were admitted to the ' '“ASST Bergamo Ovest” hospital between February 21 and May 31, 2020.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>A total of seven hundred twenty-three inpatients met the eligible ' 'criteria and were included in the study cohort. Among the inpatients who survived, the ' 'average hospital length of stay was more than two weeks, with some lasting up to three ' 'months. Among the 281 non-survivors, death occurred in 50% within five days. Survivors were ' 'those whose first aid operators recorded higher oxygen saturation levels at home. The request ' 'for first aid assistance came more than one week after symptom onset, within three days in ' '10% of cases.</jats:p>\n' ' </jats:sec><jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>In similar future scenarios, based on our data, if we aim to enhance ' 'the survival rate, we need to improve the territorial healthcare assistance and admit to ' 'hospitals only those patients who are at risk of severe illness requiring specialized and ' 'urgent interventions within two, three, or, at most, five days from the onset of symptoms. ' 'This implies that the crucial factor is, has been, and will be the ability of a healthcare ' 'system to react promptly in its entirety within a few days.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1186/s12879-024-09034-4', 'type': 'journal-article', 'created': {'date-parts': [[2024, 1, 31]], 'date-time': '2024-01-31T08:03:39Z', 'timestamp': 1706688219000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'First COVID-19 wave in the province of Bergamo, Italy: epidemiological and clinical ' 'characteristics, outcome and management of the first hospitalized patients', 'prefix': '10.1186', 'volume': '24', 'author': [ {'given': 'Bianca Maria', 'family': 'Donida', 'sequence': 'first', 'affiliation': []}, {'given': 'Flavia Simonetta', 'family': 'Pirola', 'sequence': 'additional', 'affiliation': []}, {'given': 'Roberto', 'family': 'Opizzi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Peter', 'family': 'Assembergs', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2024, 1, 31]]}, 'reference': [ { 'key': '9034_CR1', 'unstructured': 'World Health Organization., «Coronavirus - Situation report 1,» 21 Jan ' '2020. [Online]. Available: ' 'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR2', 'unstructured': 'World Health Organization, «Report of the WHO-China Joint Mission on ' 'Coronavirus Disease. 2019 (COVID-19)» 16–24 February 2020. [Online]. ' 'Available: ' 'https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR3', 'unstructured': 'World Health Organization., «Coronavirus - Situation report 31» 20 Feb ' '2020. [Online]. Available: ' 'https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200220-sitrep-31-covid-19.pdf?sfvrsn=dfd11d24_2. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR4', 'unstructured': 'World Health Organization., «WHO Director-General’s opening remarks at ' 'the media briefing on COVID-19–11 March 2020» WHO, 11 Mar 2020. ' '[Online]. Available: ' 'https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR5', 'unstructured': 'Collaborators COVID-. 19 Excess Mortality, «Estimating excess mortality ' 'due to the COVID-19 pandemic: a systematic analysis of COVID-19-related ' 'mortality 2020–21» The Lancet, Vol. %1 di %2S0140-6736, n. 21, pp. ' '02796-3, 10 Mar 2022.'}, { 'key': '9034_CR6', 'unstructured': 'Italian Ministry of Health., «Report Vaccini Anti COVID-19» 11 Apr 2022. ' '[Online]. Available: ' 'https://www.governo.it/it/cscovid19/report-vaccini/. [Accessed Dec ' '2022].'}, { 'key': '9034_CR7', 'doi-asserted-by': 'crossref', 'unstructured': 'World Health Organization., «Clinical management of severe acute ' 'respiratory infection (SARI) when COVID-19 disease is suspected» 13 Mar ' '2020. [Online]. Available: ' 'https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf. ' '[Accessed Dec 2022].', 'DOI': '10.15557/PiMR.2020.0003'}, { 'key': '9034_CR8', 'unstructured': 'World Health Organization., «Clinical management of Covid - Interim ' 'Guidance» 27 May 2020. [Online]. Available: ' 'https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5-eng.pdf?sequence=1&isAllowed=y. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR9', 'unstructured': 'European Centre for Disease Prevention and Control., «Case definition ' 'for coronavirus disease 2019 (COVID-19)» 2020, 20 Dec. [Online]. ' 'Available: ' 'https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR10', 'unstructured': 'European Union, «REGULATION, EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND ' 'OF THE COUNCIL» 27 Apr. (2016. [Online]. Available: ' 'https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679&from=EN. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR11', 'unstructured': 'Agenzia Italiana del Farmaco., «Multicenter study on the efficacy and ' 'tolerability of tocilizumab in the treatment of patients with COVID-19 ' 'pneumonia (TOCIVID-19)» 18 Mar 2020. [Online]. Available: ' 'https://www.aifa.gov.it/documents/20142/1161351/TOCIVID-19_documenti.zip?t=1589463488981&download=true. ' '[Accessed Dec 2022].'}, { 'issue': '1', 'key': '9034_CR12', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1002/rmv.2146', 'volume': '31', 'author': 'BG Marin', 'year': '2021', 'unstructured': 'Marin BG, Aghagoli G, et al. «Predictors of COVID-19 severity: a ' 'literature review». Rev Med Virol. 2021;31(1):1–10.', 'journal-title': 'Rev Med Virol'}, { 'key': '9034_CR13', 'doi-asserted-by': 'crossref', 'unstructured': 'Kermali M, Khalsa RK et al. «The role of biomarkers in diagnosis of ' 'COVID-19– A systematic review» Life Sciences, vol. 254, n. 117788, 2020.', 'DOI': '10.1016/j.lfs.2020.117788'}, { 'key': '9034_CR14', 'doi-asserted-by': 'crossref', 'unstructured': 'Izcovich A, Ragusa MA et al. «Prognostic factors for severity and ' 'mortality in patients infected with COVID-19: A systematic review» ' 'PLoSONE, vol. 15, n. 11, p. e0241955, 2020.', 'DOI': '10.1371/journal.pone.0241955'}, { 'key': '9034_CR15', 'doi-asserted-by': 'crossref', 'unstructured': 'Elshazli RM, Toraih EA et al. «Diagnostic and prognostic value of ' 'hematological and immunological markers in COVID-19 infection: a ' 'meta-analysis of 6320 patients» PLoSONE, vol. 15, n. 8, p. e0238160, ' '2020.', 'DOI': '10.1371/journal.pone.0238160'}, { 'key': '9034_CR16', 'doi-asserted-by': 'crossref', 'unstructured': 'Cattelan AM, Di Meco E et al. «Clinical characteristics and laboratory ' 'biomarkers changes in COVID-19 patients requiring or not intensive or ' 'sub-intensive care: a comparative study» BMC Infectious Diseases, vol. ' '20, n. 934, 2020.', 'DOI': '10.1186/s12879-020-05647-7'}, { 'key': '9034_CR17', 'doi-asserted-by': 'publisher', 'first-page': '100449', 'DOI': '10.1016/j.eclinm.2020.100449', 'volume': '25', 'author': 'T Fumeaux', 'year': '2020', 'unstructured': 'PDW, Fumeaux T, et al. Prognostic factors associated with mortality risk ' 'and disease progression in 639 critically ill patients with COVID-19 in ' 'Europe: initial report of the international RISC-19-ICU prospective ' 'observational cohort. EClinicalMedicine. 2020;25:100449.', 'journal-title': 'EClinicalMedicine'}, { 'issue': '2', 'key': '9034_CR18', 'doi-asserted-by': 'crossref', 'first-page': '211', 'DOI': '10.1164/rccm.167.2.211', 'volume': '167', 'author': 'American Thoracic Society', 'year': '2003', 'unstructured': 'American Thoracic Society. American College of Chest Physicians. ' '«ATS/ACCP Statement on cardiopulmonary». Am J Respir Crit Care Med. ' '2003;167(2):211–77.', 'journal-title': 'Am J Respir Crit Care Med'}, { 'key': '9034_CR19', 'doi-asserted-by': 'publisher', 'unstructured': 'Lee WW, Mayberry K, Crapo R, Jensen RL. «The accuracy of pulse oximetry ' 'in the emergency department» Am J Emerg Med. 2000;18(4):427–\u200931. ' 'https://doi.org/10.1053/ajem.2000.7330. PMID: 10919532.', 'DOI': '10.1053/ajem.2000.7330'}, { 'key': '9034_CR20', 'unstructured': 'Italian Ministry of Health., «Sorveglianza Integrata COVID-19 in Italia» ' '29 May 2020. [Online]. Available: ' 'https://www.epicentro.iss.it/coronavirus/bollettino/Infografica_29maggio%20ITA.pdf. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR21', 'doi-asserted-by': 'crossref', 'unstructured': 'Ma A, Cheng J et al. «Neutrophil-to-lymphocyte ratio as a predictive ' 'biomarker for moderate-severe ARDS in severe COVID-19 patients» Crit ' 'Care, vol. 24, n. 1, p. 288, 2020.', 'DOI': '10.1186/s13054-020-03007-0'}, { 'key': '9034_CR22', 'doi-asserted-by': 'crossref', 'unstructured': 'Ibanez-Samaniego L, Bighelli F et al. «Elevation of liver fibrosis index ' 'FIB-4 is associated with poor clinical outcomes in patients with ' 'COVID-19» J infect Dis., p. 10.1093/ infdis/jiaa355, 2020.', 'DOI': '10.1093/infdis/jiaa355'}, { 'key': '9034_CR23', 'doi-asserted-by': 'publisher', 'unstructured': 'Riccioni L et al. «Raccomandazioni Di Etica Clinica per l’ammissione a ' 'trattamenti intensivi e per la loro sospensione, in condizioni ' 'eccezionali di squilibrio tra necessità e risorse disponibili» recenti ' 'prog Med 2020, n. 111, pp. 207–11. https://doi.org/10.1701/3347.33183, ' '2020.', 'DOI': '10.1701/3347.33183'}, { 'key': '9034_CR24', 'unstructured': 'World Health Organization., «Clinical management of severe acute ' 'respiratory infection when novel coronavirus (2019-nCoV) infection is ' 'suspected: interim guidance,» 28 Jan 2020. [Online]. Available: ' 'https://apps.who.int/iris/handle/10665/330893. [Accessed Dec 2022].'}, { 'key': '9034_CR25', 'unstructured': 'Società Italiana di Malattie Infettive Tropicali., «Linee guida sulla ' 'gestione terapeutica e di supporto per pazienti con infezione da ' 'coronavirus COVID-19» Mar 2020. [Online]. Available: ' 'https://www.simit.org/images/regioni/lombardia/comunicazioni/Vademecum%20COVID-19/4.%20vademecum%201.0%20%2001.03.20.pdf. ' '[Accessed Dec 2022].'}, { 'key': '9034_CR26', 'unstructured': 'Agenzia Italiana del Farmaco., «Schede informative sui farmaci ' 'utilizzati per emergenza COVID-19 e relative modalità di prescrizione» ' '[Online]. Available: ' 'https://www.aifa.gov.it/web/guest/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19. ' '[Accessed Dec 2022].'}], 'container-title': 'BMC Infectious Diseases', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09034-4.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1186/s12879-024-09034-4/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1186/s12879-024-09034-4.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 1, 31]], 'date-time': '2024-01-31T08:05:56Z', 'timestamp': 1706688356000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09034-4'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 1, 31]]}, 'references-count': 26, 'journal-issue': {'issue': '1', 'published-online': {'date-parts': [[2024, 12]]}}, 'alternative-id': ['9034'], 'URL': 'http://dx.doi.org/10.1186/s12879-024-09034-4', 'relation': {}, 'ISSN': ['1471-2334'], 'subject': ['Infectious Diseases'], 'container-title-short': 'BMC Infect Dis', 'published': {'date-parts': [[2024, 1, 31]]}, 'assertion': [ { 'value': '24 January 2023', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 January 2024', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '31 January 2024', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'This study was submitted to and approved by the Ethics Committee of Bergamo ' '(Bergamo, BG, Italy) with the procedure’s reference “096/22”. All methods were ' 'carried out in accordance with relevant guidelines and regulations. Informed ' 'consent was obtained from all subjects and/or their legal guardian(s) in ' 'accordance with the approved ethical standards for retrospective observational ' 'study without drugs.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Ethics approval and consent to participate'}}, { 'value': 'Not Applicable.', 'order': 3, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Consent for publication'}}, { 'value': 'The authors declare no competing interests.', 'order': 4, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Competing interests'}}], 'article-number': '151'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit